98386-81-3

Basic information

• Product Name: 2-(TRIFLUOROMETHYL)CINNAMIC ACID
• Synonyms: 2-(Trifluoromethyl)cinnamic acid 98%;2-(Trifluoromethyl)cinnamicacid98%;trans-2-(Trifluoromethyl)cinnamic acid 98%;trans-3-[2-(Trifluoromethyl)phenyl]prop-2-enoic acid, (2E)-3-[2-(Trifluoromethyl)phenyl]acrylic acid;(E)-3-(2-(trifluoroMethyl)phenyl)acrylic acid;(2E)-3-[2-(Trifluoromethyl)phenyl]prop-2-enoic acid, (E)-3-[2-(Trifluoromethyl)phenyl]acrylic acid;(E)-3-(2-Trifluoromethylphenyl)-2-propenoic acid;trans-3-(2-Trifluoromethylphenyl)-2-propenoic acid
• CAS NO: 98386-81-3
• Molecular Formula: C₁₀H₇F₃O₂
• Molecular Weight: 216.16
• Mol File: 98386-81-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 199
• Boiling Point: 276.9°Cat760mmHg
• Flash Point: 121.3°C
• Appearance: /
• Density: 1.363g/cm³
• Vapor Pressure: 0.000511mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.22±0.10(Predicted)
• CAS DataBase Reference: 2-(TRIFLUOROMETHYL)CINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TRIFLUOROMETHYL)CINNAMIC ACID(98386-81-3)
• EPA Substance Registry System: 2-(TRIFLUOROMETHYL)CINNAMIC ACID(98386-81-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 98386-81-3(Hazardous Substances Data)

Usage

General Description

2-(Trifluoromethyl)cinnamic acid is a chemical compound with the molecular formula C10H7F3O2. It is a derivative of cinnamic acid, which is a naturally occurring organic compound found in cinnamon and other plants. 2-(Trifluoromethyl)cinnamic acid is widely used in the pharmaceutical industry as a building block in the synthesis of various drugs and biologically active compounds. It has also been studied for its potential anti-inflammatory and antioxidant properties. 2-(TRIFLUOROMETHYL)CINNAMIC ACID is known for its strong electron-withdrawing properties and is often used in organic synthesis as a means of introducing a trifluoromethyl group into a molecule.

InChI:InChI=1/C10H7F3O2/c11-10(12,13)8(9(14)15)6-7-4-2-1-3-5-7/h1-6H,(H,14,15)/b8-6-

Upstream product

• 141-82-2 malonic acid 
• 123486-66-8 3-<2'-(trifluoromethyl)phenyl>-2-propenal 
• 444-29-1 2-iodo(trifluoromethyl)benzene 
• 447-61-0 2-Trifluoromethylbenzaldehyde 

Relevant articles and documents

Design, Synthesis, and Anticancer Activity of Cinnamoylated Barbituric Acid Derivatives

This work deals with the design and synthesis of 18 barbituric acid derivatives bearing 1,3-dimethylbarbituric acid and cinnamic acid scaffolds to find potent anticancer agents. The target molecules were obtained through Knoevenagel condensation and acylation reaction. The cytotoxicity was assessed by the MTT assay. Flowcytometry was performed to determine the cell cycle arrest, apoptosis, ROS levels and the loss of MMP. The ratios of GSH/GSSG and the MDA levels were determined by using UV spectrophotometry. The results revealed that introducing substitutions (CF3, OCF3, F) on the meta- of the benzyl ring of barbituric acid derivatives led to a considerable increase in the antiproliferative activities compared with that of corresponding ortho- and para-substituted barbituric acid derivatives. Mechanism investigation implied that the 1c could increase the ROS and MDA level, decrease the ratio of GSH/GSSG and MMP, and lead to cell cycle arrest. Further research is needed for structural optimization to enhance hydrophilicity, thereby improve the biological activity of these compounds.

Developing piperlongumine-directed glutathione S-transferase inhibitors by an electrophilicity-based strategy

We report a case of successful design of glutathione S-transferase (GST) inhibitors via a natural product-inspired and electrophilicity-based strategy. Based on this strategy, a novel piperlongumine analog (PL-13) bearing a para-trifluoromethyl group and an α-chlorine on its aromatic and lactam rings, respectively, surfaced as a promising GST inhibitor, thereby overcoming cisplatin resistance in lung cancer A549 cells.

Design, synthesis and cytotoxic evaluation of novel imatinib amide derivatives that target Abl kinase

Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities. All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4, a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of 0.67, 0.66, 0.65, 0.59 and 0.62 μM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position compounds a21 and b1 into the active site of Abl to determine the probable binding modes